UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of February 2021 (Report No. 2)
Commission file number: 001-39957
NLS PHARMACEUTICS LTD.
(Translation of registrant’s name into English)
Alter Postplatz 2
CH-6370 Stans, Switzerland
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____
CONTENTS
On February 2, 2021, NLS Pharmaceutics Ltd. (the “Registrant”) filed Amended and Restated Articles of Association (the “Articles”), effective as of February 5, 2021, with the commercial registry of the Canton of Nidwalden, Switzerland, thereby increasing its share capital to 235,826.50 Swiss Francs with a total of 11,791,325 common shares issued and increasing its authorized share capital to a total of 117,551.80 Swiss Francs with a total of 5,877,590 common shares. The Registrant’s authorized share capital is the amount of share capital by which the Registrant’s board of directors may increase the Registrant’s share capital within two years without needing the approval of its shareholders.
The foregoing description of the Articles is qualified in its entirety by reference to the Articles and marked Articles filed as Exhibits 3.1 and 3.2 hereto, respectively, which are incorporated herein by reference.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | NLS Pharmaceutics Ltd. |
| | | |
| Date: February 8, 2021 | By: | /s/ Alexander Zwyer |
| | | Name: | Alexander Zwyer |
| | | Title: | Chief Executive Officer |
3
